Evidence map›Paper›PMID 41513131›Full record

ArticleJournal of advanced research2026

METTL4 enhances GLI1 translation through m

Weijie Sun, Weiqi Dai, Chaobo Chen, Qian Qiu, Jianqing Chen, Jiaojiao Chen, Yueyue Li, Yuqi Liu, Dengyu Han, Wenhui Mo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weijie SunDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Anhui 233000, PR China.
Weiqi DaiDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China.
Chaobo ChenDepartment of General Surgery, Xishan People's Hospital of Wuxi City, Wuxi 214105, PR China.
Qian QiuDepartment of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, PR China.
Jianqing ChenDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China.
Jiaojiao ChenDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China.
Yueyue LiDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China.
Yuqi LiuUniversity of Shanghai for Science and Technology, Shanghai 200093, PR China.
Dengyu HanUniversity of Shanghai for Science and Technology, Shanghai 200093, PR China.
Wenhui MoDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China. Electronic address: wugui502812@sina.com.
Zishu WangDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Anhui 233000, PR China. Electronic address: wzshahbb@163.com.
Yihang YuanDepartment of General Surgery, Nanjing Drum Tower Hospital Affiliated Hospital of Medical School, Nanjing University, Jiangsu 210008, PR China. Electronic address: surgeryuan@outlook.com.
Xuanfu XuDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai 200090, PR China. Electronic address: shuanfusky@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) is a major cause of cancer-related mortality. Epigenetic dysregulation, particularly through methyltransferase METTL4, plays a critical role in HCC progression. METTL4 is known to catalyze m

objectiveThis study aims to firstly investigate the role of METTL4 in the pathogenesis of HCC, and then to evaluate the antitumor efficacy of targeting METTL4 in inhibiting HCC growth and metastasis.

methodsIn a total of 802 postoperative HCC patients from four independent cohorts, we analyzed METTL4 expression in HCC tissues and its correlation with tumor staging and survival rates. Functional assays assessed the impact of METTL4 knockdown on HCC cell proliferation and metastasis, and patient-derived organoids (PDO) were used to evaluate the therapeutic efficacy of targeting METTL4. m

resultsMETTL4 was significantly upregulated in HCC tissues, correlating with higher tumor staging and poorer survival. Knockdown of METTL4 significantly inhibited HCC cell proliferation, migration, tumor growth, and lung metastasis. Meanwhile, targeting METTL4 effectively inhibited the growth of HCC PDO. METTL4-mediated m

conclusionsOur findings highlight the role of METTL4-mediated m

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMethyltransferasesZinc Finger Protein GLI1AnimalsCell Line, TumorCell ProliferationDisease ProgressionEpitranscriptomeFemaleGene Expression Regulation, NeoplasticHumansMaleMiceRNA, MessengerRNA MethylationGLI1 protein, humanMethyltransferasesRNA, MessengerZinc Finger Protein GLI1Hepatocellular carcinomaM(6)AmMETTL4mRNA translationNanoparticles

Identifiers

PMID41513131
PMCPMC13669598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.